House Passes Bill to Restrict Biotech Deals with China

The U.S. House of Representatives passed the Biosecure Act, aiming to restrict business with Chinese biotech firms like WuXi AppTec on national security grounds. The bill passed by a wide margin and now awaits Senate approval. Critics argue the bill may harm U.S. biotechnology innovation.

The U.S. House of Representatives on Monday passed a bill to restrict business dealings with several Chinese biotech companies, including WuXi AppTec and BGI, citing national security concerns. The Biosecure Act, which targets federal contracts with these firms, passed 306 to 81.

Proponents argue that the measure will protect Americans' health and genetic data and safeguard pharmaceutical supply chains. However, opponents claim the bill relies on unclear rationale and may hinder technological innovation. Representative Jim McGovern criticized the bill for lacking transparency, especially since WuXi Biologics has a facility in his district.

The bill now moves to the Senate, where its fate remains uncertain. Chinese firms, including WuXi AppTec and MGI, have condemned the bill, asserting it is based on false allegations. Industry voices warn that the legislation could negatively impact U.S. leadership in biotechnology and patient care.

(With inputs from agencies.)